EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

2016 • 29,943 citations

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

2008 • 25,031 citations

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

2017 • 14,809 citations

The blockade of immune checkpoints in cancer immunotherapy

2012 • 12,062 citations

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

2012 • 11,574 citations

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

2015 • 8,603 citations

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

2015 • 7,844 citations

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

2009 • 7,749 citations

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

2015 • 7,057 citations

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

2015 • 5,944 citations

PD-1 blockade induces responses by inhibiting adaptive immune resistance

2014 • 5,750 citations

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

2015 • 5,526 citations

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

2014 • 4,720 citations

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

2015 • 3,641 citations

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

2014 • 2,914 citations

Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

2014 • 1,552 citations

Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors

2013 • 1,135 citations

Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

2015 • 1,128 citations

Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers

2012 • 1,100 citations

Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)

2008 • 658 citations

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation

2015 • 595 citations

Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer

2015 • 407 citations

Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine

2010 • 392 citations

Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer

2013 • 313 citations

Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?

2015 • 259 citations

The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs

2015 • 219 citations

Colorectal cancer prognosis depends on T-cell infiltration and molecular characteristics of the tumor

2011 • 206 citations

Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status

2015 • 152 citations

Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR).

2015 • 121 citations